Ingevity NGVT Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $59.8M+171% | -$84.6M-294% | $43.5M+130% | -$146.5M-815% | $20.5M— | ||
| $22.7M-18.6% | $27.9M-0.4% | $28M+9.4% | $25.6M+2.8% | $24.9M-1.2% | ||
| $4.8M+6.7% | $4.5M-15.1% | $5.3M+20.5% | $4.4M+7.3% | $4.1M+95.2% | ||
| $15.5M+161% | -$25.6M-198% | $26M+719% | -$4.2M-367% | -$900K+91.3% | ||
| $2.8M— | —— | —— | $183.8M— | $0+100% | ||
| $55.6M+335% | -$23.7M— | $0+100% | -$2.5M— | $0— | ||
| $24.2M+152% | -$46.1M-203% | -$15.2M-155% | $27.8M+30.5% | $21.3M+147% | ||
| $24.5M+253% | -$16M-150% | -$6.4M+79.3% | -$30.9M-336% | $13.1M+149% | ||
| -$11.6M-36.5% | -$8.5M— | —— | —— | $8M+900% | ||
| $4.4M+129% | -$15.1M-264% | $9.2M+194% | -$9.8M-713% | $1.6M+118% | ||
| $2.2M+216% | -$1.9M-35.7% | -$1.4M-164% | $2.2M+1,200% | -$200K— | ||
| -$1.2M-100% | -$600K— | —— | -$5.4M-260% | -$1.5M+86.4% | ||
| $1.3M+152% | -$2.5M+70.2% | -$8.4M-227% | $6.6M+113% | $3.1M+255% | ||
| -$2M-102% | $97.1M-25.1% | $129.7M+64.2% | $79M+211% | $25.4M-60.6% | ||
| $10.3M-56.4% | $23.6M+98.3% | $11.9M-2.5% | $12.2M+22.0% | $10M-59.8% | ||
| $93.1M— | —— | —— | —— | $0— | ||
| $1.2M-90.6% | $12.7M+251% | -$8.4M+10.6% | -$9.4M-284% | $5.1M+82.1% | ||
| $0— | —— | —— | —— | $3.6M— | ||
| $106.3M+804% | -$15.1M+46.3% | -$28.1M-904% | -$2.8M+75.7% | -$11.5M+58.9% | ||
| $52.3M+68.2% | $31.1M— | —— | —— | $0— | ||
| $713.8M+773% | $81.8M+60.4% | $51M-23.0% | $66.2M-28.3% | $92.3M-63.7% | ||
| $718M+437% | $133.6M+10.7% | $120.7M-6.4% | $129M+28.6% | $100.3M+184% | ||
| $3.3M+313% | $800K— | —— | —— | $0— | ||
| $4.3M+378% | $900K+350% | $200K— | $0-100% | $2.6M+1,200% | ||
| $4M— | —— | —— | —— | $0— | ||
| -$61.8M+25.9% | -$83.4M+12.0% | -$94.8M-50.5% | -$63M-473% | -$11M+88.7% | ||
| $200K— | $0-100% | $500K-83.3% | $3M+114% | $1.4M+124% | ||
| $42.7M— | $0-100% | $7.3M-54.9% | $16.2M+277% | $4.3M+106% | ||
| $11.1M-43.7% | $19.7M+45.9% | $13.5M-40.3% | $22.6M+54.8% | $14.6M-40.2% | ||
| $2.5M-34.2% | $3.8M+153% | $1.5M+25.0% | $1.2M-72.7% | $4.4M+51.7% | ||
| $4.8M+6.7% | $4.5M-15.1% | $5.3M+20.5% | $4.4M+7.3% | $4.1M+95.2% | ||
| $55.6M— | —— | —— | —— | $0— | ||
| -$16.2M— | —— | —— | —— | $0— | ||
| —— | $27.33M0.0% | $27.33M0.0% | $27.33M0.0% | $27.33M— | ||
| -$14.2M-341% | $5.9M+68.6% | $3.5M-47.0% | $6.6M+173% | -$9.1M-322% | ||
| $0— | —— | —— | —— | -$6.2M-664% | ||
| $4.1M-8.9% | $4.5M0.0% | $4.5M-13.5% | $5.2M-1.9% | $5.3M+26.2% | ||
| $4.4M— | —— | $9.2M+194% | -$9.8M-713% | $1.6M— | ||
| $2.2M+216% | -$1.9M-35.7% | -$1.4M-164% | $2.2M+1,200% | -$200K— | ||
| -$8.6M+19.6% | -$10.7M+13.0% | -$12.3M-7.0% | -$11.5M+0.9% | -$11.6M+24.7% | ||
| $600K— | —— | -$2M+68.8% | -$6.4M-6,300% | -$100K+97.8% | ||
| —— | $3.68M0.0% | $3.68M0.0% | $3.68M0.0% | $3.68M-23.0% | ||
| $2.8M— | —— | $3.2M-20.0% | $4M-7.0% | $4.3M— | ||
| -$2.6M-2,500% | -$100K+93.8% | -$1.6M+72.4% | -$5.8M-5,700% | -$100K+98.7% | ||
| —— | $300K0.0% | $300K0.0% | $300K0.0% | $300K-20.0% | ||
| $8.3M-28.4% | $11.6M+17.2% | $9.9M-54.8% | $21.9M+78.0% | $12.3M-47.4% | ||
| $1.2M-90.6% | $12.7M+251% | -$8.4M+10.6% | -$9.4M-284% | $5.1M+82.1% | ||
| $24.7M— | —— | —— | —— | $0— | ||
| $0— | —— | —— | —— | $3.6M— | ||
| -$300K+25.0% | -$400K-33.3% | -$300K-50.0% | -$200K+50.0% | -$400K-300% | ||
| $4M— | —— | —— | —— | $0— | ||
| $1.8M+1,700% | $100K— | —— | —— | $2.9M+1,350% | ||
| $200K— | —— | —— | —— | $1.4M— | ||
| $5.8M+625% | $800K+33.3% | $600K+50.0% | $400K— | $0-100% | ||
| $2.5M-34.2% | $3.8M+153% | $1.5M+25.0% | $1.2M-72.7% | $4.4M+51.7% | ||
| -$12.3M-117% | $73.5M-37.6% | $117.8M+76.3% | $66.8M+334% | $15.4M-61.1% | ||
| -$12.3M-117% | $73.5M-37.6% | $117.8M+76.3% | $66.8M+334% | $15.4M-61.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Ingevity's cash flow data come from?
- Every line is extracted from Ingevity's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.